Objective: 18F FDG-PET is superior to other imaging techniques in revealing residual laryngeal cancer after radiotherapy. Unfortunately, its specificity is low, due to FDG uptake in inflammation and in anaerobic conditions. PET imaging with the amino acid-based radiopharmaceutical C11-methionine (MET) should be less influenced by post-radiation conditions. The aim of this study was to investigate the potential of MET in diagnosing recurrent laryngeal cancer after radiotherapy as compared to 18F-FDG.
growth pattern, embedded in oedema and inflammatory tissue ( Figure 1) . 1 In some patients, these features will persist over the ensuing years.
A positive biopsy, by means of endoscopy, is the gold standard for confirming residual or recurrent disease, but a negative biopsy does not necessarily exclude residual or recurrent disease. Several direct laryngoscopies may be necessary to prove the presence of residual or recurrent disease. [2] [3] [4] In addition, the tissue damage caused by biopsies may exacerbate the already existing inflammation, oedema and fibrosis. 5 Conventional imaging techniques to detect recurrent laryngeal carcinoma after radiotherapy include CT and MRI. The sensitivity of both imaging techniques ranges from 58% to 72%. 6, 7 In clinical practice, these figures may indicate that one needs to perform a direct laryngoscopy, despite negative CT or MRI findings. FDG-PET appeared to be helpful for select patients with clinical suspicion of recurrent laryngeal carcinoma after radiotherapy, when direct laryngoscopies under general anaesthesia with biopsies were indicated. 8 A systematic review by Brouwer and colleagues shows that FDG-PET can help to reveal residual disease after radiotherapy, with a sensitivity of 89% and a specificity of 74%. 3 An explanation for the relatively low specificity could be the uptake of FDG in activated macrophages. As in tumour cells, activated macrophages have an abundance of GLUT-1 receptors and will therefore have a high uptake of FDG. 9, 10 The conditions after radiotherapy are characterised by non-vital tumour cells and macrophages dominating the former tumour site, regardless of the presence of residual disease or not.
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The uptake of amino acids-methionine, for example-is high in tumour cells but low in inflammatory tissues and could therefore be a good alternative to FDG. 12 C-11 MET is an established radiopharmaceutical and has been widely used to visualise intracranial lesions. 13 Methionine (MET) has also been successfully used in visualising primary head and neck cancer. [14] [15] [16] [17] [18] In addition to preclinical studies validating MET in the evaluation of radiotherapy/chemoradiotherapy, preclinical studies also showed a fast decline for MET in the post-radiation phase. 19, 20 Autoradiography shows that MET uptake is predominantly located in viable tumour cells, with low uptake in macrophages and nonviable tumour cells. 21 In this study, we hypothesise that MET-PET is better than FDG-PET in detecting recurrent disease in patients with clinical suspicion of recurrent laryngeal carcinoma after radiotherapy.
| ME THODS

| Patients
The protocol was approved by the ethics committee as required in the Netherlands under the Medical Research Involving Human Subjects Act. All patients provided written informed consent. Two university hospitals recruited patients for the study.
Forty-eight patients with a clinical suspicion-although no obvious local residual, recurrent disease or second primary at least 3 months after completing radiotherapy/chemoradiotherapy with curative intent for a resectable T2-4 laryngeal squamous cell carcinoma-who had a clinical indication for direct laryngoscopy and biopsy under general anaesthesia were included. Suspicion of recurrent disease was raised by the patient's complaints and changes on physical examination that included fibre-optic laryngoscopy. Exclusion criteria were no younger than 18 years, a clinically evident recurrence, and pregnancy. One patient had to be excluded because parts of the PET scan registration were lost. The patient received MET-PET and FDG-PET prior to direct laryngoscopy. The maximum allowed timeframe between scans and laryngoscopy was 1 month.
| Ethical considerations
| Procedures
C11-methionine was prepared in our laboratory by 11C -methylation of L-homocysteine thiolactone using a Zymark robotic system. To this end, a solution of L-homocysteine thiolactone in a NaOH/ethanol mixture was put into a C18 cartridge followed by the passage of C11-methyl iodide. When the radioactivity on the cartridge was maximal, C11-methionine was eluted with a phosphate buffer through a second C18 cartridge and a sterile filter to a sterile vial containing saline. This end product was ready for injection and met the following radiopharmaceutical criteria-radiochemical purity > 95%, specific activity > 10 000 GBq/mmol, sterile and pyrogen free, | 125 F18-FDG was produced according to the method of Hamacher and colleagues, using an automated synthesis module. 14 The radiochemical yield was 65.9% ± 7.1% (decay corrected).
The patients were scheduled for separate C11-MET-PET only and F18-FDGPET only scans, shortly before the direct laryngoscopy.
For both scans, patients were instructed to fast for at least 6 hours.
A5 MBq/kg C11-MET or 5 MBq/kg F18-FDG was injected intravenously and again after 20 or 60 minutes (for C11-MET or F18-FDG, respectively). The scanning was performed on an ECAT EXACT HR +PET camera (Siemens/CTI Inc) at both institutions, according to the Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. 22 The scanned trajectory included skull base to the pelvis (Figures 1 and 2 ). PET Data were collected by the first author, and he was responsible for the completeness and accuracy of the reported data and analyses.
PET scans were evaluated both conservatively and sensitively. (Table 2) . The combined approach using the FDG-PET followed by the sen- The patient who was included more than five years after finishing radiotherapy had a false-positive FDG and MET-PET.
T A B L E 1 Baseline characteristics of the patients
Seventeen patients were included between 1 and 5 years after finishing radiotherapy. Using the conservative reading, the sensitivity of FDG-PET was 80.0% (95% CI = 0.6-1.0.), the specificity 60.1% (95% CI = 0.09-1.00), the PPV 65.6% and the NPV 78.1%. Twentysix patients were included between three and twelve months after finishing radiotherapy. Using the conservative reading, the sensitivity of FDG-PET was 75.3% (95% CI = 0.61-0.89), the specificity 53.3% (95% CI = 0.05-1.00), the PPV 61.5% and the NPV 73.2%.
Using the conservative reading, the sensitivity of MET-PET in the group of patients who were included between 1 and 5 years was 57.4% (95% CI = 0.37-0.77), the specificity 80.4% (95% CI = 0.32-1.00), the PPV 70.80% and the NPV 69.30%.
The sensitivity in the group of patients who were included between three and twelve months after finishing radiotherapy was 52.8% (95% CI = 0.21-0.83), the specificity 76.0% (95% CI = 0.36-1.00), the PPV 65.4% and the NPV 63.3%.
| DISCUSSION
Because the majority of recurrent laryngeal cancers after radiotherapy can be salvaged if detected in a timely fashion, early detection of recurrent disease is of importance. 23 However, it may be difficult to differentiate between recurrence and post-radiation changes. 5 In the present study, FDG-PET was able to detect recurrent laryngeal cancer after radiotherapy, with results worse than those results obtained in other studies. 6, 8, 24, 25 This can be explained by the selection of our population. In most of the studies, patients with obvious residual/recurrent disease were included, while we excluded these patients.
Three recurrent diseases were not demonstrated by PET after the conservative reading: two were not demonstrated by MET-PET, and one not by either FDG-PET or MET-PET. These recurrent diseases were also not diagnosed by a direct laryngoscopy with taking of biopsies. Two or more direct laryngoscopies were necessary to diagnose the residual cancer. This shows that a false-negative PET had no more influence on the time of laryngectomy than a traditional workup. These findings are in agreement with the literature. 5, 26 In addition to reliable detection of residual or recurrent laryngeal carcinoma after radiotherapy, PET is able to detect distant metastases. [27] [28] [29] Although the metastases were revealed both by FDG and MET-PET, they were more clearly visualised by FDG-PET.
FDG-PET is our preference for detecting distant metastases.
To make a reliable selection for direct laryngoscopy, a combination of high sensitivity and high negative predictive value is mandatory. The sensitive reading of the FDG results meets these demands.
Unfortunately, the positive predictive value is much lower. This could result in a considerable number of unnecessary direct laryngoscopies, if PET were used to select patients for this procedure.
To avoid unnecessary direct laryngoscopies under general anaesthesia, a higher positive predictive value is needed. The search for an alternative to FDG was mainly driven by a desire to improve the positive predictive value. The main goal of this study-an improvement in the positive predictive value without reducing the negative predictive value-was not achieved. The positive predictive value of MET for the conservative reading was slightly higher, although not significant, than the positive predictive value obtained with FDG.
The negative predictive of 65.5% was too low, which implies that MET-PET cannot be used to select patients for a direct laryngoscopy.
It would be interesting to know whether MET-PET is able to dis- We have no explanation for these disappointing results. It is known that recurrent disease after radiotherapy is usually scattered and embedded in inflammatory tissue. This is why we conducted this pilot study. This small study did show that even early laryngeal cancers (T1-2 glottic) were excellently visualised with MET. 14 Since the major part of this study was carried out using an older generation PET camera, one would expect that the results in this study might have been better due to the improved sensitivity of the new generation of PET cameras. The limited size of recurrent disease found should therefore not be an important reason for the low sensitivity observed.
In contrast to FDG, MET visualises more than a single pathway.
MET has a considerable non-protein synthesis part, which makes MET unsuitable for quantitative analyses. 12 However, the nonprotein synthesis pathways are more strongly activated by malignancies than inflammation. The negative effects of non-protein pathways on the visualisation of recurrent disease should therefore be limited. Although high salivary gland activity is demonstrated by MET-PET, it is unlikely that this hampered interpretation of PET, because the larynx is out of the field of the submandibular and parotid glands.
A more likely explanation could be the tumour-to-background ratio. The tumour-to-background ratio of FDG is higher than the ratio obtained with MET. 12 Although the uptake of FDG in inflammatory tissues is thought to be higher than the uptake of MET, recurrent disease is probably better detected due to the absolutely stronger uptake of FDG in a malignancy (Figures 2 and 3. ). are a serious limitation to using TYR and FET on a larger scale. [32] [33] [34] To answer the question of whether other radiopharmaceuticals are more suitable for revealing recurrent laryngeal disease after radiotherapy, studies designed like ours need to be conducted.
| CONCLUSION
